Diversity of the CD4 T Cell Alloresponse: The Short and the Long of It

Overview

Journal Cell Rep

Publisher Cell Press

Specialties Biology
Cell Biology
Molecular Biology

Date 2016 Jan 26

PMID 26804905

Citations 29

Authors

Jason M Ali

Margaret C Negus

Thomas M Conlon

Ines G Harper

M Saeed Qureshi

Reza Motallebzadeh

Richard Willis

Kourosh Saeb-Parsy

Eleanor M Bolton

J Andrew Bradley

Gavin J Pettigrew

Affiliations

Soon will be listed here.

Abstract

MHC alloantigen is recognized by two pathways: "directly," intact on donor cells, or "indirectly," as self-restricted allopeptide. The duration of each pathway, and its relative contribution to allograft vasculopathy, remain unclear. Using a murine model of chronic allograft rejection, we report that direct-pathway CD4 T cell alloresponses, as well as indirect-pathway responses against MHC class II alloantigen, are curtailed by rapid elimination of donor hematopoietic antigen-presenting cells. In contrast, persistent presentation of epitope resulted in continual division and less-profound contraction of the class I allopeptide-specific CD4 T cell population, with approximately 10,000-fold more cells persisting than following acute allograft rejection. This expanded population nevertheless displayed sub-optimal anamnestic responses and was unable to provide co-stimulation-independent help for generating alloantibody. Indirect-pathway CD4 T cell responses are heterogeneous. Appreciation that responses against particular alloantigens dominate at late time points will likely inform development of strategies aimed at improving transplant outcomes.

Citing Articles

Allorecognition Unveiled: Integrating Recent Breakthroughs Into the Current Paradigm.

Charmetant X, Pettigrew G, Thaunat O Transpl Int. 2024; 37:13523.

PMID: 39588197 PMC: 11586167. DOI: 10.3389/ti.2024.13523.

Implications of MHC-restricted immunopeptidome in transplantation.

Zhanzak Z, Cina D, Johnson A, Larsen C Front Immunol. 2024; 15:1436233.

PMID: 39035001 PMC: 11257886. DOI: 10.3389/fimmu.2024.1436233.

Heterogeneity in allospecific T cell function in transplant-tolerant hosts determines susceptibility to rejection following infection.

McIntosh C, Allocco J, Wang P, McKeague M, Cassano A, Wang Y J Clin Invest. 2023; 133(21).

PMID: 37676735 PMC: 10617766. DOI: 10.1172/JCI168465.

TCR Sequencing in Mouse Models of Allorecognition Unveils the Features of Directly and Indirectly Activated Clonotypes.

Tereshchenko V, Shevyrev D, Fisher M, Bulygin A, Khantakova J, Sennikov S Int J Mol Sci. 2023; 24(15).

PMID: 37569450 PMC: 10418307. DOI: 10.3390/ijms241512075.

Cellular activation pathways and interaction networks in vascularized composite allotransplantation.

Knoedler L, Knoedler S, Panayi A, Lee C, Sadigh S, Huelsboemer L Front Immunol. 2023; 14:1179355.

PMID: 37266446 PMC: 10230044. DOI: 10.3389/fimmu.2023.1179355.

References

Le Meur M, Gerlinger P, Benoist C, Mathis D . Correcting an immune-response deficiency by creating E alpha gene transgenic mice. Nature. 1985; 316(6023):38-42. DOI: 10.1038/316038a0. View

Nelson R, McLachlan J, Kurtz J, Jenkins M . CD4+ T cell persistence and function after infection are maintained by low-level peptide:MHC class II presentation. J Immunol. 2013; 190(6):2828-34. PMC: 3594488. DOI: 10.4049/jimmunol.1202183. View

Grazia T, Pietra B, Johnson Z, Kelly B, Plenter R, Gill R . A two-step model of acute CD4 T-cell mediated cardiac allograft rejection. J Immunol. 2004; 172(12):7451-8. PMC: 4427250. DOI: 10.4049/jimmunol.172.12.7451. View

Hughes C, Savage C, Pober J . Endothelial cells augment T cell interleukin 2 production by a contact-dependent mechanism involving CD2/LFA-3 interaction. J Exp Med. 1990; 171(5):1453-67. PMC: 2187887. DOI: 10.1084/jem.171.5.1453. View

Ciubotariu R, Liu Z, Colovai A, Ho E, Itescu S, Ravalli S . Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest. 1998; 101(2):398-405. PMC: 508579. DOI: 10.1172/JCI1117. View

Honjo K, Xu X, Kapp J, Bucy R . Evidence for cooperativity in the rejection of cardiac grafts mediated by CD4 TCR Tg T cells specific for a defined allopeptide. Am J Transplant. 2004; 4(11):1762-8. DOI: 10.1046/j.1600-6143.2004.00596.x. View

Jiang S, Herrera O, Lechler R . New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr Opin Immunol. 2004; 16(5):550-7. DOI: 10.1016/j.coi.2004.07.011. View

Yi J, Du M, Zajac A . A vital role for interleukin-21 in the control of a chronic viral infection. Science. 2009; 324(5934):1572-6. PMC: 2736049. DOI: 10.1126/science.1175194. View

Rose M . Endothelial cells as antigen-presenting cells: role in human transplant rejection. Cell Mol Life Sci. 1998; 54(9):965-78. PMC: 11147442. DOI: 10.1007/s000180050226. View

10.

Piotti G, Palmisano A, Maggiore U, Buzio C . Vascular endothelium as a target of immune response in renal transplant rejection. Front Immunol. 2014; 5:505. PMC: 4204520. DOI: 10.3389/fimmu.2014.00505. View

11.

Safinia N, Afzali B, Atalar K, Lombardi G, Lechler R . T-cell alloimmunity and chronic allograft dysfunction. Kidney Int Suppl. 2010; (119):S2-12. DOI: 10.1038/ki.2010.416. View

12.

Larsen C, Elwood E, Alexander D, Ritchie S, Hendrix R, Tucker-Burden C . Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996; 381(6581):434-8. DOI: 10.1038/381434a0. View

13.

Joffre O, Santolaria T, Calise D, Al Saati T, Hudrisier D, Romagnoli P . Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med. 2007; 14(1):88-92. PMC: 2443705. DOI: 10.1038/nm1688. View

14.

Ma W, Pober J . Human endothelial cells effectively costimulate cytokine production by, but not differentiation of, naive CD4+ T cells. J Immunol. 1998; 161(5):2158-67. View

15.

Song J, Willinger T, Rongvaux A, Eynon E, Stevens S, Manz M . A mouse model for the human pathogen Salmonella typhi. Cell Host Microbe. 2010; 8(4):369-76. PMC: 2972545. DOI: 10.1016/j.chom.2010.09.003. View

16.

Moon J, Chu H, Pepper M, McSorley S, Jameson S, Kedl R . Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity. 2007; 27(2):203-13. PMC: 2200089. DOI: 10.1016/j.immuni.2007.07.007. View

17.

Adams P, Lee H, Waldman W, Sedmak D, Morgan C, Ward J . Alloantigenicity of human endothelial cells. 1. Frequency and phenotype of human T helper lymphocytes that can react to allogeneic endothelial cells. J Immunol. 1992; 148(12):3753-60. View

18.

Crawford A, Angelosanto J, Kao C, Doering T, Odorizzi P, Barnett B . Molecular and transcriptional basis of CD4⁺ T cell dysfunction during chronic infection. Immunity. 2014; 40(2):289-302. PMC: 3990591. DOI: 10.1016/j.immuni.2014.01.005. View

19.

Brunstein C, Miller J, Cao Q, McKenna D, Hippen K, Curtsinger J . Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2010; 117(3):1061-70. PMC: 3035067. DOI: 10.1182/blood-2010-07-293795. View

20.

Callaghan C, Win T, Motallebzadeh R, Conlon T, Chhabra M, Harper I . Regulation of allograft survival by inhibitory FcγRIIb signaling. J Immunol. 2012; 189(12):5694-702. PMC: 3605772. DOI: 10.4049/jimmunol.1202084. View